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Complications of transfusionThe early recognition and management of hemorrhage shock are among the most difﬁcult tasks challenging the
clinician during primary assessment of the acutely bleeding patient. Often with little time, within a chaotic set-
ting, and without sufﬁcient clinical data, a decision must be reached to begin transfusion of blood components
inmassive amounts. The practice of massive transfusion has advanced considerably and is now amore complete
and, arguably,more effective process. This new therapeutic paradigm, referred to as damage control resuscitation
(DCR), differs considerably in many important respects from previous management strategies for catastrophic
blood loss. We review several important elements of DCR including immediate correction of speciﬁc coagulopa-
thies induced by hemorrhage and management of several extreme homeostatic imbalances that may appear
in the aftermath of resuscitation. We also emphasize that the foremost objective in managing exsanguinating
hemorrhage is always expedient and deﬁnitive control of the source of bleeding.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
During the past decade, the practice ofmassive transfusion (MT) has
expanded appreciably from simply a deﬁnition to now a more compre-
hensive management strategy for hemorrhagic shock referred to as
damage control resuscitation (DCR). This new therapeutic paradigm is
based on a broader understanding of the pathophysiology of hemor-
rhagic shock and now integrates advances from multiple disciplines
[1–6]. Recently, comprehensive transfusion guidelines for management
of hemorrhage after injury have been developed in part by the Resusci-
tation Outcomes Consortium [7], Trauma Outcomes Group, and the
Prospective Observational Multicenter Major Trauma Transfusion
(PROMMTT) studies [8,9], and these guidelines continue to be reﬁned.
Substantial reductions in mortality and blood product waste can
be demonstrated after introduction of a resuscitation strategy for
the exsanguinating patient that includes the diagnosis of speciﬁc
hemorrhage-associated coagulopathies and identiﬁcation of several
extreme metabolic imbalances that may develop as a result of severe
shock or in the aftermath of massive resuscitation [4,10,11]. Moreover,
many resuscitation principles developed in the context of care of the se-
riously injured patient are applicable to the management of severeMethodist, 1701N. Senate Blvd,
).
. This is an open access article underhemorrhage occurring as a complication in other specialties such as pe-
ripheral vascular and cardiovascular surgery, transplant surgery, critical
care, cardiology, general surgery, obstetrics, and neurosurgery.
However, clinicians who are required to treat life-threatening blood
loss may be unfamiliar with the rapid and substantial progress that has
been made and is still ongoing concerning this aspect of resuscitation
[12,13]. There are several potential explanations for this uncertainty re-
garding the management of severe hemorrhage. The deﬁnition of MT
and the manner by which MT is integrated into DCR strategies can be
arbitrary and inexact. By one typically used deﬁnition (≥10 units of
packed red blood cells within a 24-hour period), a patient may be con-
sideredmassively transfused after receiving blood at a deliberate rate of
one unit every 2 h over the course of 20 h. This is, of course, a distinctly
different clinical scenario than a patient receiving the same amount of
blood within 2 h or even less [14]. Moreover, resuscitations for massive
blood loss are rare events. For example, in our hospital DCR is initiated
most frequently by the trauma service although nomore than 5% of se-
riously injured patients require resuscitation of this magnitude1; and,
DCR may be required even less frequently to manage, bleeding compli-
cations on other services [15] (Table 1). Furthermore, a major tenet of
current DCR strategies involves administration of blood components
(plasma and platelets) in a predeﬁned ratio relative to the number of1 Similar to other centers [15]MT accounts for 75% of the total amount of blood used for
trauma patients.
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Massive transfusion events Methodist Hospital in 2013 by service line.
MBTB activations
% (N)
Component usage for MT
(% of total usage)
RBCs Plasma Cryo Platelets
Trauma 62.2% (79) 75.5% 72.0% 59.3% 65.6%
CV/PV surgery 17.3% (22) 11.8% 15.2% 25.4% 17.6%
Critical care 11.8% (15) 7.1% 7.8% 6.8% 11.3%
Cardiology 3.1% (4) 2.1% 1.2% 0.0% 0.9%
General surgery 2.4% (3) 2.3% 2.7% 8.5% 3.6%
Obstetrics 2.4% (3) 0.6% 0.2% 0.0% 0.5%
Neurosurgery 0.8% (1) 0.8% 0.8% 0.0% 0.5%
Total (127)
MBTB, Massive Blood Transfusion Protocol.
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ponents (and others such as cryoprecipitate) that maximize survival
and minimize blood component waste have been difﬁcult to determine
and are incompletely deﬁned. Complicating matters still further, newer
DCR strategies are based on goal-directed hemostatic resuscitationwith
rapid point-of-care (POC) viscoelastic assessment of coagulation [16].
Though promising with respect to outcomes, goal-directed DCR pre-
sents additional layers of complexity in that a viscoelastic coagula-
tion test requires trained personnel to perform the assay and
experienced clinicians to accurately interpret the results [17]. Lastly,
whereas the fundamental precepts of hemorrhagic shock should vary
little from one location to another, conclusions regarding many patho-
physiologic mechanisms of the host response to massive blood loss
and opinions on resuscitation strategies for catastrophic bleeding have
differed substantially in different parts of the world. For clinicians
attempting to discern the concepts and best practices of DCR, these
disparities likely intensiﬁed uncertainties regarding the process more
than any other factor. However, consensus is now emerging on several
aspects of DCR as a result of recent international collaborations among
experts in shock and resuscitation [18].
Here we examine DCR from a multidisciplinary perspective [19]
by integrating descriptions of the pathophysiology, of hemorrhage-
associated coagulopathies and the extreme homeostatic imbalances
that may appear during severe hemorrhage, or in the aftermath of
resuscitation. A comprehensive understanding of cardiovascular physi-
ological principles, hematological advances in hemostasis at amolecular
and cellular level, the capabilities of the hematological laboratory, and
developments in transfusion medicine is essential for successful treat-
ment of severe bleeding. However, we emphasize that resuscitation
of the patient in hemorrhagic shock is, in effect, a means to an end.
Deﬁnitive control of bleeding is the principal objective in any compre-
hensive resuscitation scheme for hemorrhagic shock, and therefore
DCR must not eclipse emergent endoscopic [20], surgical [21] or angio-
graphic [22] intervention [23,24].
2. Damage control resuscitation
2.1. Hemorrhage-associated coagulopathy
Predictably, disorders of hemostasis exacerbate hemorrhage and
signiﬁcantly complicate resuscitation. Dilution of platelets and coagula-
tion factors during resuscitation was previously considered to be
the major cause of hemorrhage-associated coagulopathy (technically,
resuscitation-associated coagulopathy). With the exception of transfu-
sions exceeding one blood volume (approximately 10–12 units), how-
ever, and in the absence of hypothermia and acidosis, the effect of
resuscitation-induced hemodilution on coagulation is inconsequential
[25]. Clotting factors do decline in the bleeding patient, but this decline
is often out of proportion to the reduction that can be attributed to
dilution alone [26,27]. In trauma patients, several speciﬁc hemostatic
defects have been identiﬁed that are detectable in approximately25%–56% of patients prior to resuscitation [28,29]. These bleeding
diatheses are collectively referred to as trauma-induced coagulopathy,
acute coagulopathy of trauma, acute traumatic coagulopathy, or
trauma-associated coagulopathy [30,31]. Trauma-associated coagulop-
athy (TAC) is an independent predictor of adverse outcomes such
as prolongation of I.C.U. and hospital lengths of stay, as well as a four-
fold increase in mortality [31]. The recognition of coagulopathy at
admission is crucial in that this abnormality predicts a subsequent
transfusion requirement and informs the decision to proceed with
DCR [32].
TAC is attributed to one of four basic mechanisms including, 1) a
qualitative platelet defect (particularly after traumatic brain injury
[TBI]) [33–36], 2) diffuse endothelial cell injury, 3) depletion of coagula-
tion factors and platelets through hemorrhage and deposition into inju-
ries, or 4) consumption of platelets and coagulation factors secondary
to disseminated intravascular coagulation (DIC) or hyperﬁbrinolysis
[37–49]. Trauma patients may have multiple or overlapping causes
of coagulopathy, and these will shift frequently, unpredictably, and
without warning through the course of resuscitation. Therefore,
frequent reassessment of the coagulation system by anymeans is an es-
sential component of DCR. Furthermore, TAC is unequivocallyworsened
by acidosis and hypothermia. Acidemia diminishes coagulation factor
enzymatic activity, depletes ﬁbrinogen and reduces the number of cir-
culating platelets [50,51]. Hypothermia is an independent risk factor
for death during hemorrhagic shock [52], impairing coagulation at
core temperatures b34 °C [53,54]. Indeed, the association of coagulopa-
thywith acidosis and hypothermia is underscored by the phrase, “Lethal
Triad of Trauma.” Complicating matters still further, patients may
manifest a bleeding diathesis initially but subsequently convert within
hours to a hypercoagulable state and acquire risk for thromboembolic
complications [55].
Signiﬁcant platelet dysfunction after trauma in the presence of an
otherwise normal platelet count and standard clotting studies can be
detected in a high percentage of seriously injured patients and even
more frequently in head-injured patients [34]. Compromised platelet
aggregation is observed in patientswith traumatic brain injury (TBI), as-
sociated with diminished activity of the ADP receptor, P2Y12 [33]. The
mechanism responsible for TBI-induced ADP receptor down regulation
is not clearly deﬁned, and this type of platelet dysfunction is often
overlooked in the TBI patient who is bleeding, particularly when the
platelet count is normal. In addition, acidosis inhibits platelet aggrega-
tion [56], and hypothermia reversibly decreases platelet function [57].
Qualitative defects may be exacerbated by thrombocytopenia [58].
A platelet count less than 100 × 109/L with TBI has been reported as
the strongest predictor of injury progression, a requirement for emer-
gent neurosurgical intervention, and increased mortality [59]. For all
trauma, every 50 × 109/L increase in admission platelet count is associ-
ated with an odds of death at 6 h decrease by 17% (p= 0.03, 95% conﬁ-
dence interval [CI], 0.70–0.99), whereas any platelet transfusion within
the ﬁrst 24 h is associated with a lower mortality in injured patients
compared to patients who do not receive platelets (p b 0.001; 95% CI,
0.20–0.57) [58].
Shock-mediated injury of the vascular endothelium has been exam-
ined as a mechanism of TAC. This injury also includes disruption of the
covering glycocalyx throughout the vascular space [60–64]. Negatively
charged proteoglycans, glycoproteins, and glycolipids, including signiﬁ-
cant amounts of heparin-like molecules [65,66] of the glycocalyx have a
dynamic role in a number of endothelial cell functions [67]. Glycocalyx
damage is suggested by detection of circulating levels of a heparin sul-
fate proteoglycan, syndecan-1 [68], and is associated with so-called
autoheparinization, which contributes to TAC in a small percentage
of patients [69,70]. High levels of syndecan-1 are independently
associated with increased mortality after trauma [69]. Detached endo-
thelial cells circulating in blood, and detection of speciﬁc biomarkers
indicating endothelial cell injury, including, angiopoietin-2, von
Willebrand's factor antigen, ristocetin cofactor activity, sCD40L, and
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endothelium [63] as part of a dysfunctional hemostatic response to inju-
ry. The pathophysiology of endothelial cell dysfunction in patients after
signiﬁcant trauma has not been completely deﬁned but likely involves,
enhanced expression of the endothelial protein C receptor (EPCR) and
of thrombomodulin (TM), which result in a substantial accumulation
of activated protein C (aPC) and accelerated inactivation of FVa and
FVIIIa [71]. Evidence also suggests that endothelial cell injury results
in the release of substantial amounts of stored tPA from speciﬁc endo-
thelial cell intracellular granules [63]. Furthermore, the concurrent acti-
vation of PC will also result in an increase in aPC-mediated degradation
of plasminogen activator inhibitor-1 (PAI-1), which contributes
to accumulation of tPA [64,68]. Thus, by more than one mechanism,
excess expression of endothelial anticoagulation properties in the
trauma patient destabilizes the balance between coagulation and ﬁbri-
nolysis leading to a disproportionate amount of clot lysis over clot
formation [63].
Because DIC involves unregulated thrombin andplasmin generation,
the clinical manifestation of DIC in bleeding patients will be determined
by the level of coagulation activity relative to the level of ﬁbrinolytic ac-
tivity. A deﬁciency of tissue factor pathway inhibitor (TFPI) increases
susceptibility to the development of DIC [72], but possible TFPI dys-
regulation as a mechanism of bleeding-associated coagulopathy has
not been investigated. Most often DIC is a hypercoagulable state charac-
terized by diffuse non-speciﬁc deposition of microthrombi in smaller
vessels causing a thrombotic microangiopathy, which obstructs micro-
vascular ﬂow, disrupts oxygen delivery to tissue, and results in organ
system dysfunction or failure. [72] The coagulopathy that occurs from
consumption of platelets and coagulation factors in microvascular
thrombi exacerbates hemorrhage. Fibrinolysis may compensate for
intravascular microthrombosis, and therefore antiﬁbrinolytic therapy
for bleeding-associated DIC is not recommended, except in rare cases
when ﬁbrinolysis dominates the clinical course (hyperﬁbrinolysis) [73].
Hyperﬁbrinolysis (HF) has been reported to develop in 2% to 20%, of
trauma patients, increasing to 53% in a subgroup who progress to mas-
sive transfusion [49,74,75]. However, assessment of coagulation by
viscoelastic technique demonstrates that clinically signiﬁcant HF may
actually occur less frequently, developing in under 3% of trauma pa-
tients [76,77]. HF in hemorrhaging patients, if determined by viscoelas-
tic assay, can be categorized as fulminant, intermediate, or late, resulting
in 100%, 91%, or 73%mortality, respectively [48]. Progressive hemodilu-
tion during resuscitation can decreases endogenous antiﬁbrinolytic
proteins including PAI-1, α2-antiplasmin and thrombin-activatable
ﬁbrinolysis inhibitor (TAFI), and contribute to the hyperﬁbrinolytic
propensity associated with severe hemorrhage [78,48]. Both ﬁbrin and
ﬁbrinogen degradation products in excess contribute to coagulopathy
in bleeding patients by interfering with ﬁbrin polymerization and
clot stability [79], and by blocking ADP-induced platelet aggregation
[80]. Also this bleeding diathesis is potentiated by diminished hepatic
clearance of degradation products due to pre-existing liver disease,
and hypoxic injury to the liver (shock liver). A decrease in α2-plasmin
in patients with TBI is suggested as an additional mechanism of unop-
posed plasmin formation that characterizes hyperﬁbrinolysis in this
subgroup of trauma patients [81].
2.2. Massive transfusion
2.2.1. Fixed ratio protocols
DCR focus speciﬁcally on restoration of venous return to the right
heart before the patient's physiologic reserve is exhausted in concert
with expedient correction and subsequent prevention of coagulopathies
by hemostatic resuscitation with plasma and platelets. Crystalloid infu-
sion is tightly restricted and colloid volume expanders are avoided [18].
Inmilitary settings [82], freshwhole blood is often utilized for resuscita-
tion. DCR is carried out most effectively if directed by a speciﬁc protocol
or algorithm that delineates authority and clinical criteria for activation,outlines the responsibilities of various members of the resuscitation
team, lists how and at what time points the patient is assessed, directs
the timing and coordination of certain interventions, suggests resuscita-
tion endpoints to monitor, and speciﬁes under what circumstances a
DCR is deactivated. Examples of MT prediction scores are shown in
Table 2. Scores with a greater number of variables that have been
weighted appear to be more accurate. The efﬁciency of a protocol-
directed process decreases the time to transfusion, which may be a sig-
niﬁcant factor in observed reductions in organ failure, other post-injury
complications, and mortality associated with DCR [10,83,84]. Protocols
also direct transfusion of blood components either in ﬁxed ratios or as
a goal-directed strategy.
Analyses of blood component transfusion during ﬁxed-ratio-based
DCR protocols indicate improved survival with high ratios of plasma
and platelet transfusions to RBC transfusions [10,85–88], as ﬁrst sug-
gested in 2005 (referred to as “balanced transfusion therapy”) [89]
and consistent with data subsequently reported by the U.S. Military
[90]. The optimal ﬁxed ratio of units of plasma, platelets and RBCs for
non-military DCR remains incompletely deﬁned [91–93], although like-
ly falls between 1:1:3 and 1:1:1, (plasma:platelets:RBCs). Data from
PROMMTT were used to design the recently completed Pragmatic Ran-
domized Optimal Platelet and Plasma Ratios (PROPPR; NCT01545232)
trial, which examined a 1:1:1 component transfusion ratio compared
to a lower ratio (1:1:2) [8] with survival as the primary endpoint. Of
note, the survival beneﬁt from a high plasma:PRBC ratio appears to be
similar for any massively transfused patient even if the patient does
not have a coagulopathy [94] (for which high plasma:RBC ratios were
originally implemented).
A reduction in the time toﬁrst plasma transfusion duringDCR signif-
icantly reduces mortality [95]. However, fresh frozen plasma (FFP) and
FP24 require up to 60–75min preparation that signiﬁcantly delays plas-
ma availability [96]. In contrast, stored thawed plasma, which retains
acceptable levels of all coagulation factors for up to 5 days [97–100]
can be transfused immediately. Immediate transfusion of plasma is as-
sociated with an overall reduction in the amount of plasma and other
blood components transfused during DCR and with reduced plasma
wastage [4,13,83]. Also, plasma separated fromwhole blood and stored
at 4 °C for 21 days, and referred to as liquid plasma, retains close to 90%
coagulation factor activity, and is the primary source of plasma inmany
European DCR strategies [101]. Reconstituted lyophilized plasma (LP) is
another source of this blood component that may be used immediately
for a recipient of any blood type because of dilution and neutralization
of anti-A and anti-B hemagglutinins. LP, which contains coagulation fac-
tor levels equivalent to FFP, has been used by the French Army since
1994 [102]. Presently, LP is utilized by medics of the Israeli Defense
Force for resuscitation of combat casualties in hemorrhagic shock
[9], and previously LP was carried for a similar purpose by U.S. Special
Operations Forces in Afghanistan [103].
Hemostatic resuscitation for massive hemorrhage will necessitates
extensive use of AB plasma until a recipient blood type can be deter-
mined. However, the requirement for AB plasma is not as stringent as
the requirement for groupOblood. To prevent exhaustion of anABplas-
ma supply by DCRs, group A plasma has been used in DCR before blood
type is known without signiﬁcant transfusion reactions or detrimental
effects on outcomes and is now advocated [104–106]. Concern is miti-
gated by the fact that the most commonly encountered blood group
in a recipient will be group A. Also, anti-B titers are generally low in
group A plasma donated by males, hemolytic transfusion reactions in
non-group A recipients after transfusion of platelets that have been
suspended in group A plasma are rare, and DCR patients typically re-
ceive several units of group O RBCs with plasma, which decreases the
risk of hemolysis due to ABO group mismatch [107].
Bleeding-associated coagulopathymay occur secondary to the rapid
development of hypoﬁbrinogenemia [27,108–112], although the ﬁbrin-
ogen concentration belowwhich hemostasis may no longer be effective
has not been established [113]. Fibrinogen is depleted in the process
Table 2
MT prediction scores.
Prediction score Clinical criteria Lab criteria Imaging criteria Comment
Trauma Associated Severe Haemorrhage
(TASH) Score [244,245]
▪ SBP
▪ HR
▪ Male gender
▪ Unstable pelvic FX
▪ Femur FX
▪ Hgb
▪ BE
FAST Variables are weighted to yield a possible score between 0 and 28; TASH
scores are transformed into a probability of MT by a logistic function;
for example TASH ≥ 16 points indicates a probability of MT N 50% [246].
Assessment of Blood Consumption
(ABC) Score [247]
▪ SBP
▪ HR
▪ Penetrating mechanism
None FAST One point given to deﬁned abnormalities for each variable; possible
score 1 to 4; MT prediction threshold ≥ 2
Cincinnati Individual Transfusion
Trigger Study (CITT) [248]
▪ SBP
▪ Temp
▪ Hgb
▪ INR
▪ BE
None INR most predictive (odds ratio, 16.7) for any transfusion and highly
predictive for the need for MT (odds ratio, 11.3).
Massive Transfusion Score (MTS) [249]a ▪ SBP
▪ HR
▪ Temp
▪ Penetrating mechanism
▪ INR
▪ Hgb
▪ BE
FAST Validates variables in other scores using the Prospective Observational
Multicenter Major Trauma Transfusion (PROMMTT) study cohort.
Emergency Transfusion Score [250] ▪ SBP
▪ Age
▪ Unstable pelvic FX
▪ Mechanisma
None FAST Variables weighted; also considers admission from scene as a criteria;
risk of E.D. transfusion
Low b 3, intermediate risk = 3; N3.
Prince of Wales Hospital/Rainer
(PWH/Rainer) Score [251]
▪ SBP
▪ HR
▪ GCS
▪ Displaced pelvic FX
▪ Hgb
▪ BE
CT
or
FAST
Variables weighted to yield possible score between 0 and 18; MT
prediction threshold is score ≥ 6
Vandromme [252] ▪ SBP
▪ HR
▪ Lactate
▪ Hgb
▪ INR
None Only predictive model that incorporates lactate.
All variables equally weight for possible score 0 to 5; all combinations or
clinical measures alone yielded lower predictive probability.
Schreiber [253] ▪ Penetrating mechanism ▪ Hgb
▪ INR
None Based on military databases; each variable equally weighted
Larsen [254] ▪ SBP
▪ HR
▪ Hgb
▪ BE
None Based on military databases; each variable equally weighted
Hgb, hemoglobin; BE, base excess; FX, fracture; SBP, systolic blood pressure; HR, heart rate; FAST, focused abdominal sonography for trauma.
a Trafﬁc accident or fall from height (N3 m).
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existing liver disease or hypothermia. Furthermore, depletion of ﬁbrin-
ogen will be compounded by plasmin-mediated degradation
of ﬁbrinogen. Although ﬁbrinogen is resistant normally to plasmin,
hyperﬁbrinogenolysis can develop as plasmin reaches abnormally high
levels during DCR [40]. Also, plasmin-mediated ﬁbrinogen degradation
is accelerated by the acidosis that frequently complicates DCR [114,
115]. Cryoprecipitate is the principal component transfused during DCR
to manage suspected hypoﬁbrinogenemia (or possibly acquired ﬁbrino-
gen dysfunction). A 200 mL–10 unit dose of cryoprecipitate will deliver
2.5 g of ﬁbrinogen and will elevate ﬁbrinogen levels in a 70 kg adult by
approximately 70 mg/dL. Four units of plasma (600 mg ﬁbrinogen/unit)
is equivalent to a 10-unit dose of cryoprecipitate [116]. If resuscitation
with plasma is initiated early and transfusion of these components
is continued at a high plasma:RBC ratio, then a quantity of ﬁbrinogen
will be infused that approaches the amount of a standard dose of
cryoprecipitate [117]. In the course of DCR, cryoprecipitate may then
be used if ﬁbrinogen repletion is still required, but further volume ex-
pansion is not.
2.2.2. Goal-directed protocols
Patients treated empirically for hemorrhage-associated coagulopa-
thy with blood components in ﬁxed ratios may receive blood products
they donot need, or in excess ofwhatwas required to correct a bleeding
diathesis, creating exposure to unnecessary or excessive risk [118,119];
and other patientsmay not receive a product that was indicated, ormay
not receive it in a timely manner [120]. Routine evaluation of the coag-
ulation system by standard laboratory test of coagulation are performed
on platelet-poor plasma and do not reﬂect the important contribution
of cellular elements to coagulation [121]. Moreover, these tests have
not been validated for accuracy in bleeding patients [122]. Prothrombin
fragment 1.2 and thrombin-antithrombin complexes have been used as
markers of thrombin generation in the setting of hemorrhage, but these
may be unpredictably inﬂuenced by other variables [123]. Measures ofcoagulation more relevant to DCR may include assessment of speciﬁc
physical properties such as rate of clot formation, clot strength, and
the resistance of the newly formed clot to lysis. The use of systems to
assay these properties and to monitor and guide transfusion therapy
in hemorrhaging trauma patients is referred to as goal-directed DCR.
Three systems, SONOCLOT®, thromboelastography (TEG®;
Haemonetics Corp, Niles, IL, USA), or rotational thromboelastometry
(ROTEM®; Tem International GmbH, Munich, Germany), are used in
clinical laboratory or point-of-care (POC) coagulation testing as an inte-
grated assessment of the kinetics of clot formation and lysis, and the
physical properties of clot strength and elasticity in vitro, which more
accurately reﬂect hemostasis in vivo.
POC viscoelastic coagulation tests do not, in fact, provide critical data
at the immediate onset of a DCR andwithoutmodiﬁcationmay not pro-
vide data any sooner than conventional tests [124]. However, as a DCR
progresses these assays permit a more speciﬁc determination of the
blood product required and a more exact, usually less estimate of the
amount needed to reverse any identiﬁed defect in hemostasis rather
than transfusions of plasma, cryoprecipitate and platelets in a ﬁxed
ratio to empirically and non-speciﬁcally treat coagulopathy. In the
TEG system, goal-directed resuscitation involves the use of rapid-TEG
(r-TEG®) to diagnose and describe post-injury coagulopathy and to
guide blood product replacement. For r-TEG tissue factor is added
with kaolin to activate coagulation, and recent data suggest that r-TEG
can identify coagulation abnormalities very early after injury [125].
Blood products may be transfused in a ﬁxed ratio initially for patients
presentingwith uncontrolled hemorrhage, with subsequent focused in-
tervention based on r-TEG data, as it becomes available. The next com-
ponent transfusion based on the r-TEG data may include additional
thawed plasma (10–20 mL/kg) for a prolonged R value (designated
TEG-ACT for a r-TEG assay) (N1 min) indicating coagulation factor deﬁ-
ciency or depletion, or if markedly prolonged (N1.5 min), 30 mL/kg of
thawed plasma. However, 1 U apheresis platelets would be transfused
instead if the MA b 50 mm or 2 U apheresis platelets if MA b 45 mm,
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tionalﬁbrinogenMA b 14mm, or anα-angle b 52° suggestingﬁbrinogen
deﬁciency. Ly30 N 8% suggests hyperﬁbrinolysis for which an anti-
ﬁbrinolytic agent, started at the time of admission, would be continued,
or if a Ly30 N 8% occurs in association with elevated α-angle or MA
(reactive ﬁbrinolysis), would be immediately discontinued [126].
Goal-directedDCR has been reported to reduce bleeding, signiﬁcant-
ly diminish transfusion requirement, and substantially improve out-
comes [96,127]. Additional potential beneﬁt of a speciﬁc and rapid
correction of coagulation abnormalities is amore effective and complete
restoration of physiological homeostasis, which improves outcomesdue
to attenuation of an auto-inﬂammatory response [128]. Implementation
of POC viscolastography-based protocols for management of hemor-
rhage in cardiovascular surgical patients has been associated with a
reduction in perioperative transfusion requirements and transfusion-
related adverse events, a decreased incidence of thromboembolic
complications, and improved patient outcomes, including increased 6-
month survival [129]. However, a recent systematic review of 55 studies
on POC viscoelastic assays for trauma patients, not all including patients
undergoing DCR, concluded that the effect of this approach on blood
product transfusions, mortality, and other patient outcomes remain un-
proven in randomized trials [130]. Presently, a prospective, randomized
study (NCT01536496 [131]) comparing viscoelastic assay with conven-
tional coagulation testing (aPTT, INR, platelet count, ﬁbrinogen level, D-
dimer) for diagnosis of post-injury coagulopathy and to guide resuscita-
tion has recently completed enrollment of subjects. A viscoelastic assay-
based strategy, in fact, is now endorsed by several relevant international
societies and incorporated into transfusion guidelines from these
groups [132–134].
2.2.3. Coagulation factor concentrates
Because coagulation factor concentrates do not require time to thaw,
are not restricted serologically, and obviate transfusion-related compli-
cations, they have been considered as an alternative to blood compo-
nents for hemostatic resuscitation during DCR [135]. Plasma-derived
or recombinant products available inmany countries include,ﬁbrinogen
concentrate (RiaSTAP®; CSL-Behring), 3-factor prothrombin complex
concentrate (PCC; Proﬁlnine SD®; Grifols Biologicals Inc), 4-factor PCC
(unactivated Kcentra®; CSL-Behring or activated FEIBA NF®; Baxter
Healthcare Corp), FXIII concentrate (Corifact®; CSL-Behring), and re-
combinant activated FVII (NovoSeven RT®; Novo Nordisk A/S).
Fibrinogen concentrate given during resuscitation to patients
experiencing massive blood loss effectively and rapidly controls
hemorrhage-associated coagulopathy, which correlates with signiﬁcant
improvement in coagulation viscoelastographic parameters, and sub-
stantially reduces the requirements for RBC, FFP, and platelet transfu-
sions. Fibrinogen concentrate improves diminished clot strength
thought to be caused by impaired platelet-ﬁbrinogen interactions,
which can be readily detected by viscoelastic assay. However, at very
high ﬁbrinogen concentrations an opposite effect may occur [136],
which must be considered during DCR. A vial of lyophilized ﬁbrinogen
concentrate is stored at room temperature and typically contains 1.0 g
of ﬁbrinogen that is reconstituted in 50 mL sterile water for infusion.
Controlled prospective comparisons of cryoprecipitate and ﬁbrinogen
concentrate in management of hemorrhagic shock are lacking [137].
The Fibrinogen in Trauma Induced Coagulopathy Trial (FI in TIC Trial;
ClinicalTrials.gov Identiﬁer: NCT01475344) is a multicenter, double-
blind, placebo controlled, randomized pre-hospital pilot study in
Europe that will examine the efﬁcacy of pre-hospital administration
of ﬁbrinogen concentrate [138]. In Europe, ﬁbrinogen concentrate is
now used in place of allogeneic blood products as a ﬁrst-line treatment
for hypoﬁbrinogemia [139–144]. Fibrinogen concentrate is commer-
cially available in the U.S. and approved by the FDA to treat hereditary
ﬁbrinogen disorders. However, ﬁbrinogen concentrate to correct ac-
quired ﬁbrinogen deﬁciency complicating hemorrhagic shock has not
been approved by the FDA [145],An association between low FXIII levels and increased bleeding
has been noted in cardiac surgery and other clinical settings [146].
Supra-physiological concentrations of factor XIII ranging from 150% up
to 600% have been shown to increase clot ﬁrmness, accelerate clot
formation, and increase clot stability in vitro [147]. Administration of
FXIII concentrate with ﬁbrinogen concentrate has been considered in
the management of massive hemorrhage [148,149]. In some patients
undergoing DCR, an acquired FXIII deﬁciency is suggested by persistent
coagulopathy and diminished clot strength despite adequate ﬁbrinogen
levels and platelets, and administration of FXIII concentrate may prove
effective for this clinical state [135].
Prothrombin complex concentrates (PCCs) include vitamin K-
dependent factors, FII, FVII, FIX, and FX. PCC products are considered
either three-factor PCCs (containing a negligible concentration of FVII)
or four-factor PCCs (with a higher concentration of FVII); also products
differ inwhether FVII is activated or requires entry into a functioning co-
agulation system for activation after injection [150]. Technically, newer
PCC products should be considered 6-factor PCCs as most contain two
additional vitamin K covalently modiﬁed factors, protein C and protein
S. Also, measureable amounts of other proteins, including albumin
and, in particular, antithrombinmay be present.. Thromboembolic com-
plications associated with PCCs include deep venous thrombosis, DIC,
microvascular thrombosis and myocardial infarction [151]. Inclusion
of protein C and protein S prevents excessive thrombin generation
and thereby mitigates these thrombotic risks. Reversal of Trauma In-
duced Coagulopathy Using Coagulation Factor Concentrates or Fresh
Frozen Plasma (RETIC Trial; NCT01545635) is a prospective open-
label, parallel-group, monocentric study that evaluates 200 severely
traumatized patients (ISS N 15) randomized to treatment of coagulopa-
thy detected by ROTEMwith FFP alone, ﬁbrinogen concentrate alone, or
either one combined with prothrombin complex concentrate, or FXIII
concentrate [152]. Administration of PCC with ﬁbrinogen concentrate
to cardiovascular surgical patients has been associated with decreased
incidence of blood transfusion and thrombotic/thromboembolic events
[153].
Recombinant FVIIa was initially developed and utilized for man-
agement of hemophilia A or B with inhibitors to FVIII or FIX. Off-
label use of rFVIIa in the U.S. signiﬁcantly increased approximately
10 years ago, particularly in cardiovascular surgery such that by
2008, one in four uses of rFVIIa was in response to bleeding during
open heart surgery [154]. At that time the cost of one-time adminis-
tration of rFVIIa (assuming a weight of 70 kg) was $25,712 USD
[155]. In trauma patients, a large manufacturer-sponsored trial
(CONTROL Trial) involving 150 international sites, designed to assess
the potential for mortality and morbidity beneﬁts associated with use of
rFVIIa for refractory bleeding after injury, was terminated when an inter-
im data analysis predicted a low likelihood of observing a signiﬁcant dif-
ference in the primary mortality end point [117,155]. From a further
analysis of a large and comprehensive cohort involved in placebo-
controlled trials of rFVIIa, it was reported that treatment with high
doses of rFVIIa on an off-label basis signiﬁcantly increased the risk of arte-
rial thromboembolic events (e.g., coronary artery thrombosis), especially
among the elderly [156]. Also, effectiveness of rFVIIa for hemostatic
control in the setting of spontaneous intracranial hemorrhage, liver trans-
plantation or hepatobiliary surgery, or for gastrointestinal hemorrhage
in patientswith end-stage liver disease remains unproven and is associat-
ed with increased risk of thrombotic complications [157].
2.2.4. Antiﬁbrinolytics
Tranexamic acid (TXA) has been shown to decrease the need for
blood transfusion by one-third in patients undergoing high-risk elective
surgery [158], diminish post-partum hemorrhage following vaginal
delivery and Cesarean section [159], and reduce chest tube drainage
and blood component transfusion in cardiac surgery patients [160],
although the association of TXA with thromboembolic complications
remains uncertain [161]. Currently, a large pragmatic randomized
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Trial [WOMAN]; NCT00872469 [162]), expecting to enroll 15,000 sub-
jects by February 2015, will further examine the effectiveness
of TXA in obstetrical hemorrhage. Also, TXA has been evaluated in trau-
ma patients in a large international randomized placebo-controlled
trial, the Clinical Randomization of an Antiﬁbrinolytic in Signiﬁcant
Haemorrhage-2 (CRASH 2) trial [163]. CRASH-2 involved 274 centers
located in 40 countries and enrolled 20,211 subjects who either had
signiﬁcant hemorrhage or were at risk for signiﬁcant hemorrhage. All-
cause 28-day mortality was reduced 1.5% in the TXA-treated group
(14.5%) compared to the placebo group (16.0%), while death due to
hemorrhage was 4.9% in the TXA group compared to 5.7% in the control
group (RR, 0.85; 95% CI, 0.76–0.96; p = 0.0077) [163,164]. These
data yield a number needed to treat of 67 to save one life. In a much
smaller sub-group of patients presenting with SBP ≤ 75 mm Hg, all-
cause 28-day mortality was 30.6% for the TXA group compared to
35.1% for the placebo group (RR, 0.87; 99% CI 0.76–0.99).
CRASH-2 inclusion criteria were based on a systolic blood
pressure b 90 mm Hg or heart rate N 110 beats/min. However, of the
very large number of patients screened for eligibility (20,255), an un-
usually small number of patients were excluded (14; 0.0.07%) [165].
Moreover, 90% of all deaths related to trauma occurred in countries
where standardized trauma care or advanced resuscitation protocols
generally do not exist [166]. In addition, approximately half of the pa-
tients receiving TXAwere not actually bleeding,which possibly explains
why there was no reduction in the amount of blood transfused in
the TXA group compared to the control group. Also the modest injury
proﬁle of the CRASH-2 cohort may have introduced a conservative
bias against the TXA effect [167]. Other limitations identiﬁed in the
CRASH-2 study include the absence of a description of injury severity
in treatment and control groups and omission of coagulation testing,
particularly with regard to identiﬁcation of hyperﬁbrinolysis [168].
More importantly, an absolute increase in mortality was observed if
TXA was begun 3 h after injury [164]. The Clinical Randomisation of
an Antiﬁbrinolytic in Signiﬁcant Haemorrhage Intracranial Bleeding
Study (CRASH-2 IBS) was a prospective randomized controlled trial
nested within the CRASH-2 trial. One hundred and thirty-three patients
fulﬁlled the inclusion criteria for the CRASH-2 trial and also had TBI in-
dicated by GCS ≤ 14 and a CT scan compatible with TBI. Data here sug-
gest TXA signiﬁcantly reduces extension of intracranial hemorrhage
compared to controls [169]. To further examine the effects of TXA in
TBI, the Tranexamic Acid for the Treatment of Signiﬁcant Traumatic
Brain Injury: an International Randomised, Double Blind Placebo Con-
trolled Trial (CRASH-3; NCT01402882 [170]) was begun in September
2011 with a planned enrollment of 10,000 patients with TBI and esti-
mated to be completed by January 2017.2.3. Complications associated with DCR
2.3.1. Acidosis
Lactic acidosis (pH ≤ 7.20 [171]) decreases cardiac contractility and
provokes dysrhythmias, which, in effect, impose cardiogenic shock
on hypovolemic shock in the exsanguinating patient. Acidemia also de-
sensitizes peripheral vasculature adrenergic receptors to endogenous
catecholamines disabling compensatory mechanisms in response
to hemorrhagic shock [172–174], stimulates inﬂammation, and sup-
presses immunity [174]. Other adverse effects of severe acidemia
include, in particular, inhibition of platelet activation, diminished
coagulation factor activity [50,175], and accelerated breakdown of ﬁ-
brinogen [114]. Crucial phospholipid-coagulation factor complex inter-
actions are destabilized by excess H+ ions thereby drastically reducing
factor activity [176]. Thus, mortality increases predictably with succes-
sive increases in base deﬁcit. Moreover, most all of the detrimental
effects of acidemia are compounded, and survival is further reduced
by hypothermia (core temperature b 34 °C) [177].Unlike bicarbonate administration, Tris(hydroxymethyl)-
aminomethane (THAM) more effectively corrects the deep acid–base
imbalance of lactic acidosis associated with hemorrhagic shockwithout
lowering intracellular pH, reducing serum ionized calcium, or affecting
serum osmolality [174]. The initial loading dose of a 0.3 mol/L-solution
of THAM acetate = lean body-weight (kg) × base deﬁcit (mmol/L);
maximum 24 h-dose is 15 mmol/kg, or 3.5 L for a 70 kg patient [178].
Treatment of acidosis with THAM will distort the anion gap, reducing
the usefulness of this number in determination of different treatment
strategies during DCR.
2.3.2. Hypothermia
A decrease in core body temperature increases mortality of patients
in hemorrhagic shock. The enzymatic speciﬁcity constants of coagula-
tion factors in hemostatic pathways and platelet activity are negatively
affected to a signiﬁcant degree by hypothermia. Coagulation factor
activity is reduced approximately 10%–15% for each 1 °C drop in tem-
perature, which is exacerbated by factor depletion secondary to dilution
or consumption [54,179]. However, the activity of endogenous antico-
agulants, tissue factor pathway inhibitor, antithrombin, and protein C,
are also modiﬁed by hypothermia [176]. Hypothermia has a more im-
portant clinical effect on coagulation by inhibiting von Willebrand
factor-platelet glycoprotein Ib-IX-V interactions [180]. TEG or ROTEM
can be performed at the patient's actual core temperature, in contrast
to standard assays performed after serum has been warmed to 37 °C.
TEG for example, may reveal a prolonged r-time (enzymatic reaction
time), lower K value (rate of clot formation), and lower α-angle
(clot formation time) [181,182]. Hypothermic-mediated inhibition of
clotting times and clotting rate synergize with hemorrhage-mediated
reduction in clot strength (MA by TEG determination), which explains
in part the signiﬁcant worsening of hemorrhage-associated coagulopa-
thy caused by reduced core body temperature [182]. Hyperﬁbrinolysis
has been suggested as a potential mechanism of hypothermia-
mediated coagulopathy [183], but accelerated clot lysis does not appear
to be involved in this process when interrogated by viscoelastography
[54].
In the hypovolemic patient, mild hypothermia may increase car-
diac output and oxygen demand, whereas moderate or severe hypo-
thermia can depress myocardial contractility and reduce cardiac
output [184]. The reduction in cardiac output is often exacerbated by
arrhythmias from cold-induced conduction abnormalities [185], such
as hypothermia-induced Osborn waves that may precede ventricular
ﬁbrillation [186]. More commonly hypothermic patients develop supra-
ventricular arrhythmias, and atrial ﬁbrillation is frequently the arrhyth-
mia observed in patients with severe hypothermia [187].
Metabolism is signiﬁcantly diminished in hemorrhaging patients and
consequently heat production is reduced limiting passive rewarming
[188]. Furthermore, external rewarming methods help to prevent heat
loss, but transfer virtually noheat to the patient. Hypothermia is perpet-
uated or made worse by infusion of room-temperature ﬂuids or cold
blood components. For example, a patient will need to generate an ad-
ditional 16 kcal to warm 1 L of room temperature (21 °C) crystalloid to
37 °C. If the patient cannot generate this additional heat because of
diminished oxygen consumption due to shock, then infusion of room
temperature-ﬂuids is equivalent to a 16 kcal/L-heat loss, which will
decrease the body temperature of amildly hypothermic patient approx-
imately 0.3 °C for every 2 L of infused crystalloid [189]. Counter-current
ﬂuid warmers enable the infusion of up to 800 mL of saline, or 1 unit of
blood, per minute at a temperature of 37 °C–40 °C, equivalent to trans-
fusing 5–8 kcal of heat per liter, or 18 kcal to 28 kcal of heat/12 units
transfused [188,190].
2.3.3. Divalent cation deﬁciencies
Reduced circulating concentrations of calcium and magnesium due
to citrate toxicity are common adverse events in DCR. High transfu-
sion rates often exceed the liver's capacity to clear the infused citrate,
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disease or impaired hepatic function fromhypothermia [191]. Citrate ac-
cumulation during DCR and citrate-mediated hypocalcemia are often
made worse by dilution of calcium. Hypocalcemia reduces myocardial
contractility and impairs maintenance of vasomotor tone. Hypomagne-
semia also develops during DCR due to citrate accumulation and
dilution. Hypomagnesemia and hypocalcemia are associated with dis-
ruption of myocardial repolarization characterized by a prolonged a QT
interval and a risk for development of torsades de pointes [192,193].
Intravenous calcium gluconate or calcium chloride may be adminis-
tered empirically for every 4–8 units of PRBCs or plasma transfused to
prevent the development of severe hypocalcemia, although this has
not been evaluated in clinical trials. A 10mL-ampule of calcium chloride
has 3-times the amount of calcium(270mg) and 3-times the osmolarity
(2,000 mOsm/L), as a 10-mL ampule of 10% calcium gluconate (90 mg;
680 mOsm/L). Magnesium for i.v. injection is supplied as 50% or 12.5%
solutions of magnesium sulfate containing 500 mg/mL (4 mEq/mL) or
120 mg/mL (1 mEq/mL) of elemental magnesium, respectively.
2.3.4. Storage lesion
The length of time blood is stored before it is transfused correlates
with an increase in multiple organ failure, systemic inﬂammatory
response syndrome, increased infection, and increased mortality
[194–198]. The progressive deterioration in many erythrocyte biophys-
ical and metabolic properties, collectively referred to as red cell storage
lesion [196,199–202], develops largely as a result of suppression of RBC
metabolic activity. Exhaustion of energy (ATP) leads to intracellular
acidosis, 2,3-DPG depletion, membrane Na+/K+-ATPase failure, band
3 damage (responsible for chloride shifts and the transport of CO2 by
RBCs), accumulation of reactive oxygen intermediates, lipid peroxida-
tion, depletion of nitric oxide, and loss of parts of the plasmamembrane
with deformation of erythrocyte shape [203,204]. [203] This collection
of changes reduces the capacity of stored RBCs to carry and deliver
oxygen to tissue and also indirectly promotes a systemic proinﬂam-
matory state by inducing innate immune activation [205], and by gen-
erating procoagulant bioactive phospholipids that are pro-
inﬂammatory and associated with an increased risk of acute lung
injury.
Metabolism in stored blood is restored rapidly after transfusion, but
the capacity initially of transfused RBCs to efﬁciently transport oxygen
to recipient tissue may be signiﬁcantly impaired [206]. For example
the length of time required to regenerate 2,3-DPG is in vivo, although
typically of minimal clinical consequence may not be within the brief
time frames and extreme conditions of DCR. In addition a higher
afﬁnity of hemoglobin for oxygen due to low levels of 2,3-DPG is exac-
erbated by hypophosphatemia [207,208], a common electrolyte abnor-
mality induced by hemorrhagic shock. Also, incomplete reduction
of accumulated methemoglobin in stored blood [209] that has been
transfused [210] contributes to potentially a signiﬁcant fall in P50 during
DCR. Thus a patient could remain acidotic despite apparent adequate
perfusion because of the high afﬁnity of hemoglobin for oxygen and a
reduction in ofﬂoading of oxygen in the periphery [211]. This storage
lesion-related defect in oxygen delivery is compounded by hypother-
mia, which shifts the oxyhemoglobin dissociation curve to the left
(Bohr affect) increasing the afﬁnity of hemoglobin for oxygen still fur-
ther. In addition to these metabolic abnormalities, morphologic change
in stored erythrocytes from ﬂexible biconcave discs to rigid echinocytes
and spheroechinocytes decreasesmicrovascularﬂowdue to obstruction
of capillaries. Furthermore, RBC-mediated regulation of microvascular
blood ﬂow mediated by release of nitric oxide (NO) and adenosine tri-
phosphate (ATP), is abolished by storage [212].
2.3.5. Acute lung injury
Improved early survival associated with high plasma:RBC ratio
resuscitations to preemptively treat hemorrhage-associated coagu-
lopathies may be abrogated by an increase in late hospital mortalitysecondary to multisystem organ failure [213]. The leading cause of
transfusion-related mortality is acute lung injury (TRALI) that develops
during or within 6 h after transfusion of one or more units of blood or
blood components, including platelets [214]. TRALI represented 38% of
conﬁrmed transfusion-related fatalities reported to the FDA in the past
ﬁve ﬁscal years, although there has been a decrease in TRALI fatalities,
from 17 (45% of conﬁrmed transfusion-related fatalities) in FY2012, to
14 (37%) in FY2013 [215]. The risk of TRALI develops due to a dose-
dependent exposure to anti-HLA class II, or anti-human neutrophil anti-
gen (HNA) antibodies in donor plasma. Platelet transfusion carries the
risk of a plasma-mediated TRALI by content of the transfusion alone,
but because platelets are stored at room temperature complications
secondary to pathogen contamination are more problematic.
Transfusion of plasma also imparts higher risk for development of
transfusion-associated circulatory overload (TACO). TACO during DCR
occurs by infusion of blood components at a high rate, in large volumes,
or both, and is characterized by the acute onset of hypoxia, tachypnea,
tachycardia, and rapidly falling SpO2 [216]. The rate of TACO caused by
all blood products ranges from approximately 1% to 8% [217,218], but
may actually be higher than recognized [219]. Predictably, TACO is
also associatedwith a history of congestive heart failure, coronary artery
disease, previous coronary bypass surgery, and atrial ﬁbrillation [220].
Differentiating between TACO and TRALI is primarily based on deter-
mining whether transfusion-related pulmonary edema is due to in-
creased hydrostatic pressure (TACO) or is caused by an alveolar ﬂuid
accumulation due auto-inﬂammatory pathology (TRALI) [220]. Eleva-
tion of BNP or NT-proBNP has been shown to be both sensitive and spe-
ciﬁc markers of TACO [221].
2.3.6. Ischemia–reperfusion injury
Rapid restoration of normal blood ﬂow to hypoperfused tissue by
DCR can be complicated by a distinct pathologic process referred to as
reperfusion injury. The pathogenesis of reperfusion injury involves
regional and systemic autoinﬂammatory reactions [222,223] due to
non-speciﬁc activation of the coagulation/ﬁbrinolysis system as well
as activation of innate immune processes, in concert with down regula-
tion of endogenous anticoagulants [224] and inhibitors of inﬂammation
[225,226]. This process is mediated by dissemination of constitutive in-
tracellular molecules released from disrupted cells in areas of severe
ischemia and damaged tissue. Several unrelated andmultifunctional in-
tracellular and extracellular molecules, as well as certain interleukins,
heat shock proteins, and others exhibit these properties [227–229]. All
possess similar molecular component structures referred to as DAMPs
(or, damage-associated molecular pattern). DAMPs are recognized by
a family of receptors associatedwith innate immunity known as pattern
recognition receptors (PRRs). Of note, a signiﬁcant portion of RBCs
stored for long periods release free heme that is recognized by PRRs as
a DAMP ligand resulting in activation of the recipient's innate immune
system and creating the potential for systemic autoinﬂammatory tissue
damage and organ failure [199].
Serum levels of HMGB1, the prototype DAMP molecule, increase
in hemorrhagic shock [230–232]. HMGB1 binds to a speciﬁc PRR, toll-
like receptor 4 (TLR4) that is expressed on several cell types such as
dendritic cells, neutrophils, macrophages, lymphocytes, endothelial
cells, and platelets. A HMGB1-TLR4 interaction induces proinﬂammato-
ry activities [233,234] which mediate, in part, an autoinﬂammatory
response expressed clinically as a systemic inﬂammatory response syn-
drome (SIRS) [235,236]. HMGB1 also demonstrates speciﬁc interactions
with the hemostatic system, speciﬁcally upregulation of TM expression
and activation of PC leading to aPC-mediated inhibition of thrombin
generation and consumption of PAI-1 [49]. These activities may con-
tribute to modulation of coagulation by hypoperfusion.
The consequences of a systemic autoinﬂammatory syndrome are
diffuse interstitial edema and cellular swelling. Marked splanchnic
hypoperfusion is a characteristic feature of the compensatory mecha-
nisms that operate in response to massive blood loss. Subsequent
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cant bowel edema [237] and may also lead to hepatic dysfunction
[236] (so-called, shock liver). Bowel edema during reperfusion occurs
early [237] leading to intraabdominal hypertension (IAH) that may
progress to intra-abdominal compartment syndrome, deﬁned as IAH
associated with organ failure. Right ventricular (RV) preload is also
diminished by IAH-mediated reductions in inferior vena cava blood
ﬂow [238,239]. Moreover, in response to increased RV afterload,
acute RV dilatation may develop causing a decrease in ejection fraction.
Also, RV dilatation impinges on the ventricular septum, which due to
ventricular interdependence decreases left ventricular preload and
consequently further reduces cardiac output [240,241].
3. Conclusion
MT for catastrophic blood loss is a rare event. Also, an exact deﬁni-
tion of MT, uniform guidelines that specify for whom MT is indicated,
in what manner this complex intervention is accomplished, and the
meaningful outcomes that should be expected from MT all remain in-
completely deﬁned. Paradoxically, an increase in mortality has been
associated with increasing number of units transfused, and the admin-
istration of massive amounts of this expensive and limited resource
is associated with substantial risk for several non-lethal, yet still formi-
dable complications. Also, among patients who do survive, MT is inde-
pendently associated with an unfavorable long-term outcome, and a
substantial proportion of post-resuscitation patients endure signiﬁcant
functional deﬁcits one year after injury [242]. In contrast to this bleak
perspective, however, is the fact that continued advances in resuscita-
tion practices and incorporation of MT into comprehensive DCR proto-
cols have led to progressive improvement in survival for patients in
profound hemorrhagic shock. Indeed, before 1990 resuscitation of
patients with severe acute blood loss resulted in low survival rates, on
the order of 10% to 40%, while survival currently, with implementation
of comprehensive DCR programs, is reported from 65% to as high as
92% [243].
The success of current DCR strategies is founded on advances from
laboratory and clinical investigations that have more thoroughly eluci-
dated the pathogenesis of hemorrhagic shock and clariﬁed the mecha-
nisms of hemorrhage-induced coagulopathy. New paradigms such as
hemostatic resuscitation have fundamentally redeﬁned the manage-
ment of catastrophic blood loss. To continue to reﬁne the principles of
resuscitation, additional high-quality prospective randomized interven-
tion studies, guided by initial acquisition of prospective observational
data, will be necessary. And, whereas in previous decades the manage-
ment of exsanguinating hemorrhage required clinicians to possess sim-
ply a passing familiarity with MT, effective resuscitation practices now
mandate an understanding of a signiﬁcantly more complex and consid-
erably more comprehensive strategy for care of the bleeding patient.
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